The developmental receptor NOTCH plays an important role in various human cancers as a consequence of oncogenic mutations. Here we describe a novel mechanism of NOTCH-induced tumor suppression involving modulation of the deacetylase SIRT1, providing a rationale for the use of SIRT1 inhibitors to treat cancers where this mechanism is inactivated due to SIRT1 overexpression. In Ewing sarcoma (ES) cells, NOTCH signaling was abrogated by the driver oncogene EWS-FLI1.
INTRODUCTION
NOTCH signaling is an evolutionary conserved pathway involved in tissue patterning and cell specification during normal development. It is initiated following interaction of a cell surface expressed ligand (JAG1, JAG2, DLL1, 3 and 4) with a trans-membrane monomeric NOTCH receptor (NOTCH1-4). Binding of the ligand is followed by two successive proteolytic cleavage steps catalyzed by tumor necrosis factor-D-converting enzyme and the presenilin-J-secretase complex that release the NOTCH intracellular domain (NICD) to the cytoplasm. Upon translocation to the nucleus, NICD activates the transcription factor CSL. The amplitude and duration of the NOTCH response is regulated by acetylation of NICD on specific lysine residues (1) . Only few CSL targets are known, most prominently the HES and HEY family of transcriptional repressors. In many mammalian cell types, the NOTCH pathway enhances stem cell potential and suppresses differentiation, while in others it exerts an opposite role suppressing tumor development (2) . Oncogenic NOTCH pathway activation by mutation occurs in many cancers including T-cell leukemia and a variety of solid tumors including breast, colorectal, ovarian, and non-small cell lung cancer. Accordingly, a number of pharmacological NOTCH inhibitors are currently in early clinical development. However, the consequences of activated NOTCH signaling are cell type specific and there is a growing list of tissues and neoplasms in which NOTCH activation has a tumor suppressive effect, including keratinocytes, tumors of the prostate, liver, skin, lung, gastrointestinal stromal tumors, a wide range of B-cell malignancies, and in Ewing sarcoma (ES) (3) . Currently, the mechanisms of tumor suppressive NOTCH signaling remain unknown.
ES pathogenesis is driven by the chimeric ETS oncogene EWS-FLI1. EWS-FLI1 acts as an aberrant
oncogenic transcription factor with both activating and repressive gene regulatory properties (4) . We have previously reported that EWS-FLI1 represses JAG1 expression keeping NOTCH signaling off (5) .
We found that silencing of EWS-FLI1 results in activation of tumor cell autonomous NOTCH signaling leading to a strong transcriptional induction of HEY1, which was paralleled by activation of the tumor Author Manuscript Published OnlineFirst on October 3, 2014; DOI: 10.1158/0008-5472.CAN- suppressor TP53 and consequently up-regulation of the cell cycle inhibitor p21 and cell cycle arrest (3) . We showed that HEY1 was sufficient to elicit a TP53 response in ES cell lines, but the mechanism of TP53 activation remained unknown.
We here demonstrate that knockdown of EWS-FLI1 and induction of HEY1 result in TP53 acetylation.
Carboxy terminal acetylation by p300 was demonstrated to be essential for TP53 transcriptional activity (6) . Consequently, factors that lead to deacetylation of TP53 interfere with TP53 stress response (7) . We now report the sirtuin SIRT1 as a HEY1 repressed deacetylase preventing TP53 acetylation downstream of suppressed NOTCH signaling in ES and other tissues in which NOTCH acts tumor suppressive.
Sirtuins are an evolutionary highly conserved protein family homologous to yeast silent information regulator 2 (sir2), and link cellular metabolism to tissue homeostasis and differentiation. Sirtuins have recently attracted considerable interest due to their role in inflammation, protection from neurodegenerative diseases, organismal longevity, and their emerging importance for cancer (8) . Of the seven members of this family in man, SIRT1, 3, 6, and 7 localize mainly to the nucleus, while SIRT2 resides exclusively in the cytoplasm, and SIRT4 and 5 in mitochondria. SIRT1, 2, 3 and 5 catalyze NAD + -dependent deacetylation of targets, while SIRT4 and 6 mediate ADP-ribosylation of protein substrates. SIRT1 has originally been identified as a class III histone deacetylase removing histone H1K26, H3K9, H3K56 and H4K16 acetylation marks thus facilitating heterochromatin formation. In addition, it plays a role in the repression of euchromatic gene regulation as part of a corepressor complex with the demethylase LSD1 and associated proteins. Among others, this complex binds to CSL and represses genes regulated by the NOTCH signaling pathway including HEY1 (9).
Additionally, SIRT1 can modulate NICD activity by de-acetylation as demonstrated in endothelial cells (1) . Gene regulation by SIRT1 is also effected by deacetylation of other transcription factors including AR, FOXO, E2F1, HIC1, BCL6, NF-.B, and notably TP53 [for review (10) ]. SIRT1 physically interacts with TP53 and deacetylates Lys382 thus reducing TP53´s transcriptional activity (7, 11) . Knockdown of SIRT1 allows for TP53 acetylation which is an indispensable prerequisite for the destabilization of the TP53-MDM2 interaction inducing transcriptional activity and enabling TP53 stress response (12) .
We here report that modulation of SIRT1 by HEY1 provides a feed-back mechanism that couples NOTCH signaling to TP53 activation in tissues in which NOTCH activity acts tumor suppressive. We demonstrate that, in ES, SIRT1 expression is specifically confined to metastases, and that pharmacological inhibition of SIRT1 activity efficiently kills SIRT1 positive ES cells in vitro and prohibits growth and migration of tumor cells in vivo.
MATERIALS AND METHODS

Cell lines, transfections and drug treatments
Cell lines of this study are summarized in Supplementary Table S4A . All cell lines were verified by STR analysis and are routinely subjected to mycoplasma and SMRV testing in regular intervals. ES cell lines and keratinocytes were transfected with LipofectAMINE Plus reagent (Invitrogen, Groningen, The Netherlands) and subjected to puromycin selection (1μg/mL) the next day. 96 hours posttransfection, puromycin selected cells were harvested, washed and subjected to RNA and protein extraction. "697" and Nalm-6 were transfected by electroporation (Gene Pulser XCell, Bio-Rad, Hercules, CA, USA) using commercial electroporation buffers from BioRad. Tnv-6 (DundeeCell, Dundee, UK) and MG132 (Alexis, Biochem, San Diego, Ca, USA) were used at concentrations and time periods indicated in the figures. Plasmids and siRNA targeting sequences used in the study have previously been published and are listed in Supplementary Table S4B and C.
Proliferation and viability assays
Cell viability was assessed using the colorimetric MTT metabolic activity assay. Briefly, ES cells (2 ×   10 4 cells/well) were cultured in 96-well plates at 37 °C and exposed to varying concentrations of Tnv- TP53 was precipitated with either CM1 or DO1 antibodies and probed with either acetylation specific or DO1 antibodies.
Reporter gene assays
For promoter activity analysis, TC252 ES cells were plated at an initial concentration of 10 4 cells/ml into 24-well plates. Cells were transiently transfected with 50ng of each SIRT1-firefly reporter construct plus 100ng of pSport HEY1 and pSuper empty vector, using Lipofectamine TM (InVitrogen, Carlsbad, CA, USA). Luciferase reporter assays were then performed using Renilla as internal control.
All plasmids employed are listed in Supplementary Table S4B .
Gene expression analysis
Changes in gene expression profiles upon knockdown of EWS-FLI1 were followed on Affymetrix HGU133A arrays (Affymetrix, Inc.; Santa Clara, CA,USA ) as previously reported (3). Table S2 ). In addition, formalin-fixed paraffin-embedded tissue blocks from 14 paired primary ES tumor and corresponding metastasis tissues were obtained from the University College London (see also Supplemental Materials).
Tissue processing, antibody staining (Supplementary Table S4C ), and interpretation of staining results were performed as previously described (13) . Two pathologists blind to the origin and identity of cases independently evaluated the percentage and intensity of stained cells (IM, ALB). Statistical differences in staining patterns were evaluated employing the 2x2 Fisher exact (two-tailed) probability test. Rockville, MD) analysis was performed as described previously (15) .
Zebrafish embryo xenotransplantation and in vivo Tnv
RESULTS
Identification of candidate genes mediating HEY1 induced TP53 stabilization downstream of EWS-
FLI1
We previously showed that the NOTCH effector HEY1 stabilizes and activates TP53 in ES upon silencing of EWS-FLI1, but the mechanism behind remained unknown (3). Since TP53 stability is largely regulated by post-translational modifications (PTMs), we hypothesized that HEY1 represses a TP53 interacting protein involved in the destabilization of TP53. We considered either a repression of the MDM2/MDM4 ubiquitin ligase complex (Supplementary Results and Supplementary Fig. S1 ), or of an enzyme involved in destabilizing post-translational TP53 modification. encoding DNA dependent protein kinase; YEATS4, whose product GAS41 is involved in dephosphorylation of TP53 Ser366 (19) ; PPA1, stabilizing MDM4 and dephosphorylating TP53 at Ser15 (20, 21) ; PPP2R5C, a component of protein phosphatase 2A dephosphorylating TP53 at various residues including Thr55, Ser37 and Ser46 (22) (23) (24) , and SIRT1, a type III deacetylase known to target histone and non-histone proteins including TP53. While suppression of PRKDC is expected to perturb the DNA damage checkpoint (25) , HEY1 mediated suppression of GAS41, or protein phosphatases 1 and 2, and specifically of the deacetylase SIRT1 has the potential to lead to TP53 stabilization and activation. We observed a marked upregulation of SIRT1 RNA expression in 59 primary ES samples as compared to 89 normal tissues (Fig. 1A) , and acetylation of TP53 in response to EWS-FLI1 knockdown and ectopic HEY1 expression in the ES cell line TC252 (Fig. 1B) . Since acetylation and deacetylation play a central role in the regulation of the TP53 pathway (16), we therefore focused our further analysis on SIRT1.
SIRT1 mediates TP53 stabilization by HEY1 downstream of NOTCH and of EWS-FLI1 silencing
Ectopic HEY1 consistently reduced SIRT1 expression leading to TP53 stabilization and consequently to the induction of CDKN1A expression in wildtype TP53 cell types, for which NOTCH activation has been reported to act tumor suppressive. This is demonstrated for three ES cell lines (TC252, VH64 and WE68) (Fig. 1C) , the B-ALL cell line 697, the B-cell lymphoma cell line Nalm-6 , and primary human keratinocytes lacking endogenous HEY1 expression ( Supplementary Fig. S2 ). SIRT1 modulation is dependent on the concentration of ectopic HEY1 as demonstrated in HEK293 cells carrying doxycycline inducible Flag-tagged HEY1, where it was completely reversible upon release from doxycycline dependent HEY1 induction ( Supplementary Fig. S3A ). Conversely, knockdown of endogenous HEY1 in the osteosarcoma cell line U2OS by siRNA increased SIRT1 accompanied by TP53 modulation (Supplementary Fig. S3B ). These results indicate that the mechanism of TP53 activation by HEY1-mediated SIRT1 suppression is not restricted to ES but also operative in other tissues and tumors. Consistent with HEY1 acting downstream of activated NOTCH signaling, ectopic NICD1 expression also induced SIRT1 down-regulation and TP53 stabilization (Fig. 1D) . To confirm dependence of EWS-FLI1 dependent SIRT1 regulation on HEY1 in ES cells, we performed EWS-FLI1 knockdown in the absence and presence of siRNA to HEY1. Silencing of EWS-FLI1 by shRNA resulted in a marked induction of HEY1 and a strong down-regulation of SIRT1 which was completely rescued upon concomitant inhibition of HEY1 expression (Fig. 1E) .
HEY proteins are known to preferentially bind to class B E-box sequences (26, 27) . The SIRT1 promoter region contains a (GACGTG) motif at -373 base pairs from the transcriptional start site (Fig.   1F ). In reporter gene assays with a 562 base pair SIRT1 promoter fragment driving luciferase expression in TC252 cells, HEY1 reduced the activity more than 3-fold. This transcriptional repressive effect was completely lost upon mutation of the E-box element ( 
Inhibition of SIRT1 leads to Ewing sarcoma cell death in vitro
Modulation of SIRT1 in ES cells was sufficient to induce acetylation of TP53 and activation of TP53 target genes such as CDKN1A ( Fig. 2A) , as also observed upon HEY1 expression (Fig. 1C) . In fact, ectopic expression of increasing amounts of SIRT1 in the presence of HEY1 was able to abolish HEY1 induced TP53 acetylation already at the lowest levels (Fig 2B) . These results suggest that SIRT1 expression in ES is involved in functional impairment of TP53 activity, which can be restored by activation of the NOTCH signaling pathway through HEY1 induction upon knockdown of EWS-FLI1.
We next tested for the impact of SIRT1 modulation on cell fate of ES cells. Knockdown of SIRT1 but not of SIRT2 induced TP53 acetylation and cell death in TC252 cells (Fig. 3A) . This result suggested that SIRT1 expression may serve as a promising pharmacological target in ES. We therefore tested CAN-14-1736 the sensitivity of ES cell lines to the small molecule SIRT1/2 inhibitor Tenovin-6 (Tnv-6) (29). As shown in Fig. 3B , Tnv-6 killed ES cell lines with IC50 values between 0.8 and 8.0μM. The lowest IC50 values were found in cell lines with wildtype TP53 which also expressed the highest levels of SIRT1, consistent with the induction of acetylated TP53 and of CDKN1A as a marker of TP53 transcriptional activation (Fig. 3C) . Dependence of Tnv-6 induced cell death on TP53 was best demonstrated by rescue of cell viability without any change in SIRT1 expression levels if TP53 was knocked down before Tnv-6 treatment in wildtype TP53 TC252 cells (Fig. 3D) . Cell death induction by Tnv-6 depended on SIRT1 but not on SIRT2, since SIRT2 knockdown failed to rescue TC252 cell death induced by drug treatment (Fig. 3E) . Together, these results indicate that ES cells are highly sensitive to Tnv-6 treatment, and that the level of sensitivity depends on the presence or absence of intact TP53 and SIRT1.
The SIRT1/2 inhibitor Tnv-6 inhibits Ewing sarcoma growth and spread in a zebrafish xenotransplantation model Since inhibition of SIRT1 was able to kill ES cell lines we tested Tnv-6 for tumor inhibitory activity in an established xenotransplantation model in zebrafish embryos (30). Two cell lines with high and low SIRT1 expression and distinct Tnv-6 in vitro sensitivity (Fig. 3B) , the wildtype TP53 cell line TC252 and the TP53 mutant cell line A673, were fluorescently labeled with mCherry and injected into the yolk sac of fli1:EGFP transgenic zebrafish embryos. Implanted embryos were either treated with solvent (DMSO) or 6 μM Tnv-6 for 4 days, and growth and spread of tumor cells through the embryo body were monitored by confocal microscopy (Fig. 4A) . Fig. 4B combines the results for all embryos injected in 3 independent replica experiments in a scatter plot that visualizes the distance and direction of migration for each object (cluster of tumor cells) for each embryo. As quantified in Fig.   4C , Tnv-6 not only significantly reduced tumor burden (p<0.0001), but also significantly inhibited migration of TC252 cells (p<0.0001) but not of A673 cells. These data show that pharmacological inhibition of SIRT1 interferes with ES growth and migration in vivo. 
SIRT1 expression in Ewing sarcoma primary tumors and metastases
To validate SIRT1 expression in primary tumors, we screened 392 paraffin-embedded formalin-fixed ES samples on two series of tissue microarrays (TMA1 and TMA2, Supplementary Fig. S4 Fig. S4 ). Fig. 5A provides examples for the distinct staining patterns obtained. 131 (48%) primary tumors tested negative and 54 (20%) showed only mild staining, while 65 (24%) and 22 (8%) displayed moderate and strong nuclear SIRT1 staining, respectively (Fig. 5B) .
Focusing on primary tumors from patients with localized disease 109 (51%), 41 (19%), 53 (25%), and 11 (5%) showed no, mild, moderate, and strong staining. Corresponding numbers obtained for primary tumors from patients who presented with metastases at diagnosis were 12 (35%), 10 (29%), 5 (15%), and 7 (21%), suggesting a non-significant tendency towards higher positivity in patients with primary disseminated disease (p=0.550). The site of metastasis was known for the informative primary tumors from patients with metastatic disease on TMA1 in 29 cases (Supplementary Table   S2 ). Here, primary tumors associated with lung metastasis and primary tumors from patients with bone metastases tested positive in 50% and 40%, respectively. Strikingly, this tendency turned into a significant difference (p<0.001) when focusing on 26 informative metastasis-derived samples (Fig. 5B, last column) . Here, two thirds of metastases showed SIRT1 expression in more than 10% of cells (8 moderately positive, 9 highly positive) while 4 samples tested negative and 5 metastases showed SIRT1 positivity in less than 10% of cells (Fig. 5B) . To validate our finding of increased SIRT1 positivity in ES metastases, we tested an independent series of 14 paired tissue samples for SIRT1 expression by IHC (Table 1, cases 1-14) . Including four paired samples available from TMA1 and TMA2 (Table 1 , cases 15-18), we found lung metastases to score positive in 88% and bone marrow metastases in 55% of cases similar to the frequency in the primary tumors of these metastatic patients (61%), a frequency twice as high as observed on the tissue micro arrays for the primary tumors of patients with localized disease. These results suggest that ES metastases, specifically lung metastases are predominantly highly positive for SIRT1 by IHC, and that this positivity can frequently already be observed in the corresponding primary tumors at diagnosis.
Since this finding may imply a prognostic relevance of SIRT1 positivity, we independently tested a third previously published cohort of 43 ES patients with complete clinical follow-up for a median of 154 months for SIRT1 expression by IHC (TMA3; Supplementary Fig. S4 ) (14) . Six of 32 localized tumors (19%) and six of 11 tumors from patients with metastatic disease at diagnosis (55%) tested highly or moderately SIRT1 positive. Intriguingly, five year survival probability for the 12 SIRT1 positive patients was 25% as compared to 70% for the 31 SIRT1 negative patients (Supplementary   Table S3 and Supplementary Fig. S5 ). Although these results call for larger prospective studies to validate the potential prognostic importance of SIRT1 in ES, our combined data strongly imply SIRT1 as a candidate therapeutic target in ES patients with metastatic disease.
Discussion
The NOTCH signaling pathway is well known for its complexity. Its role in cancer has been extensively studied in the context of oncogenic NOTCH mutations but little was known about its tumor suppressive mechanisms. We here report on the mechanism by which HEY1 downstream of activated NOTCH induces TP53, and demonstrate that this mechanism is not only operative in ES but also in other malignancies and tissues for which NOTCH activity has been linked to tumor suppression. We human keratinocytes, leading to TP53 acetylation, stabilization and transcriptional activation. SIRT1 has previously been described to be involved in the epigenetic transcriptional repression of the HEY1 promoter. In the absence of NOTCH activation, SIRT1 forms a co-repressor complex with LSD1, CoREST1 and CtBP1 leading to concerted repressive histone H4K16 deacetylation and H3K4 demethylation at the HEY1 promoter. Since we find SIRT1 (shown here) and also LSD1 (31) to be consistently expressed in ES, and concomitantly HEY1 to be completely turned off (5), this mechanism is likely operative in ES. Upon activation and nuclear translocation of NICD and binding to the NOTCH regulated transcription factor CSL, this co-repressor complex is replaced by mastermindlike (MAML) and co-activators including the histone lysine acetyltransferase p300/CBP leading to transcriptional activation (9) . In addition, NICD stability has been reported to be prolonged by acetylation which is modulated by SIRT1 with negative consequences on duration and amplitude of the NOTCH response (1). Also, SIRT1 represses NOTCH1 transcription from a highly conserved region in the NOTCH1 promoter in endothelial cells (32) . By demonstrating suppression of SIRT1 expression by HEY1, our results add an important negative feed-back loop to NOTCH-driven gene regulation (Fig.   6 ). It also adds a putative feed-back mechanism of potential prognostic value to the regulation of TP53. Not only does SIRT1 modulate TP53 stability and activity, but also TP53 has been demonstrated to suppress SIRT1 expression through transcriptional repression via binding to a TP53 response element in the SIRT1 promoter (33) , and post-transcriptional regulation via TP53 activated microRNA hsa-mir-34a (34) (Fig 6) . Interestingly, hsa-mir-34a and two further SIRT1 regulatory microRNAs, hsamir-132 and hsa-mir-93 were recently described components of a favorable prognostic signature in ES (35) . Since we find SIRT1 positivity in ES mainly associated with metastases, it is intriguing to speculate that the TP53/hsa-mir-34a/SIRT1 gene regulatory module plays a role in the suppression of CAN-14-1736 of the embryos, Tnv-6 likely inhibited active tumor cell migration, consistent with SIRT1´s documented role in the regulation of cortactin (36) . This migration inhibitory effect could not be studied in vitro, because of the strong cytotoxic effect of Tnv-6 and of SIRT1 knockdown observed in the ES cell lines. Cell death induction upon perturbation of SIRT1 expression or activity was mainly due to activation of TP53 and could be rescued upon knockdown of TP53. In fact, sensitivity to pharmacological SIRT1 inhibition was highest in wildtype TP53 cell lines, which are representative of more than 90% of ES (37) . However, also mutant TP53 cell lines proved sensitive to Tnv-6 treatment, albeit at much higher doses, which is likely due to SIRT1´s broad transcriptional and epigenetic role in genome-wide gene regulation as has previously been observed (29) . Although it cannot be excluded that part of the in vitro cytotoxic activity of Tnv-6 may be due to a non-SIRT1/non-TP53 related activity such as induction of autophagy as previously observed in CLL (38), it did not play a role in the zebrafish xenotransplantation model. Here, drug activity was dependent on high SIRT1 expression and the presence of wildtype TP53.
Our immunohistochemical study performed on a total of four independent ES cohorts reproducibly transcriptional regulation (32). 9. SIRT1 feeds back on its negative regulator HEY1 by epigenetically silencing its promoter (9) . While NOTCH activation via HEY1 is able to suppress SIRT1, several additional mechanisms are known to activate or repress SIRT1 including transcriptional regulators HIF1 and 2 and HIC1 (39, 41) , microRNAs (40) , kinases (42) (43) (44) (45) (46) (47) , and sumoylation (48) that integrate microenvironmental signals with SIRT1 expression/activity and may be responsible for the specific upregulation of SIRT1 observed in ES lung metastases (10). 11. EWS-FLI1 directly binds to the SIRT1 
